Johnson & Johnson's Biotech Investments May Impact Future Earnings
Johnson & Johnson (JNJ) has lowered its adjusted earnings guidance for 2026 due to the impact of recent biotech investments, including the acquisition of Firefly Bio and a partnership with Sail Biomedicines. The company now expects 2026 adjusted EPS between $10.96 and $11.11 per share, down from previous guidance of $11.60 to $11.75. While this year's earnings will be affected by about 64 cents a share, the real impact is expected in 2027 with an estimated EPS reduction of up to $1.36 due primarily to potential acquisition costs related to Sail. The unusual structure of these deals creates what analysts call an "upside-down" earnings signal: greater scientific progress could lead Johnson & Johnson to invest more, increasing short-term financial pressure but potentially offering long-term value. The company's revenue guidance remains stable at $100.8 billion to $101.4 billion for 2026. Shares fell in after-hours trading following the announcement as investors grapple with the implications of these strategic moves.
Tickers: $JNJ